Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Japan Orders More Relenza Flu Vaccine From GSK

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare has ordered more Relenza (zanamivir) flu vaccine from British drug maker GlaxoSmithKline. For this flu season, the Ministry has prepared the vaccine for 3 million people, which is one-third of Tamiflu (oseltamivir phosphate) stockpiles. However, among the flu cases reported nationwide, 44.5 percent are infected with H1N1 type virus, which is resistant to Tamiflu. Worried about a possible shortage of Relenza, the Ministry requested additional vaccine from GSK. The drug maker has asked drug wholesalers in Japan to adjust shipping based on inventory conditions, and MHLW has cautioned medical facilities to avoid large orders of the drug. (Click here for more - Japanese language

Table

View full table

Tags:
Latest Headlines

Deal Watch: Bristol Adds To Vaccines ‘Repertoire,’ Takes ‘Scenic’ View Of Cellular Pathways

Navigating A Transition Year: Five Takeaways From Pfizer’s Q1 Call

Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal

Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs

See All
UsernamePublicRestriction

Register

SC069950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By